Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov55510.25208/vdv555ArticlesСтатьиReview ArticleSkin melanoma: from systematic biology to the personalized therapyМеланома кожи: от системной биологии к персонифицированной терапииRukshaT GРукшаТ Г

д.м.н., зав. кафедрой патофизиологии с курсом клинической патофизиологии

tatyana_ruksha@mail.ruAksenenkoM BАксененкоМ Б

к.м.н., ассистент кафедры патофизиологии с курсом клинической патофизиологии

SergeyevaYe YuСергееваЕ Ю

профессор, кафедры патофизиологии с курсом клинической патофизиологии

FefelovaYu AФефеловаЮ А

доцент, кафедры патофизиологии с курсом клинической патофизиологии

Krasnoyarsk State Medical UniversityГБОУ ВПО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Миниздрава России15022013891NO1 (2013)№1 (2013)4811032020Copyright ©; 2013, Ruksha T.G., Aksenenko M.B., Sergeyeva Y.Y., Fefelova Y.A.Copyright ©; 2013, Рукша Т.Г., Аксененко М.Б., Сергеева Е.Ю., Фефелова Ю.А.2013Ruksha T.G., Aksenenko M.B., Sergeyeva Y.Y., Fefelova Y.A.Рукша Т.Г., Аксененко М.Б., Сергеева Е.Ю., Фефелова Ю.А.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/555

Systematic biology is a new field of biomedicine based on the integrative approach to molecular mechanisms of the operation of living systems including in case of the development of pathological processes. In this connection, up-to-date therapeutic approaches to skin melanoma treatment can be considered on the basis of key changes in intermolecular interactions taking place during tumor development.

Системная биология является новой областью биомедицины, в основе которой лежит интегративный подход к рассмотрению молекулярных механизмов функционирования живых систем, в том числе при развитии патологических процессов. В этой связи современные терапевтические подходы в отношении меланомы кожи могут быть рассмотрены на основании ключевых изменений межмолекулярных взаимодействий, происходящих при формировании данной опухоли.

systematic biologyskin melanomasignal pathsсистемная биологиямеланома кожисигнальные путиGalas D., Hood L. Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive, personalized, preventive and participatory (P4) medicine. Interdisciplinary Biocentre 2009; 6: 1—4.Sverdlov E.D. Vzglyad na zhizn' cherez okno genoma. M.: Nauka 2009. [Свердлов Е.Д. Взгляд на жизнь через окно генома. М: Наука 2009.]Sol A. del, Balling R., Hood L. et al. Disease as network pertubations. Curr Opinion Biotechnol 2010; 21: 556—571.Stelling J., Sauer U., Szallasi Z. et al. Robustness of cellular functions. Cell 2004; 118: 675—685.Zhu X., Gerstein M., Snyder M. Getting connected: analysis and principles of biological networks. Genes & Development 2007; 21: 1010—1024.Diamandis M., White N.M.A., Yousef G.M. Personalized medicine: marking a new epoch in cancer patient management. Molec Cancer Res 2010; 8: 1175— 1187.Schallreuter K.U., Salem M.A., Gibons N.C. et al. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 1: epidermal H2O2/ONOO--mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels. FASEB J 2012; 26: 247—2470.Guan H., Jia S.-F., Zhou Z. et al. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005; 11: 2008—2017.Nikolaou V.A., Stratigos A.J., Flaherty K.T. et al. Melanoma: new insight and new therapies. J invest Derm 2012; 132: 854—863.Kumar V. Pathologic basis of disease. Philadelphia: Saunders Elsevier; 2010.Wu R.Q., Zhao X.F., Wang Z.Y. Novel molecular events in oral carcinogenesis via integrative approaches. J Dental Res 2011; 90: 561—572.Huang S., Ernberg I., Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Seminars in Cell and Developmental Biology 2009; 20: 869—876.Kreeger P.K., Lauffenburger D.A. Cancer systems biology: a network modeling perspective. Carcinogenesis 2010; 31: 2—8.Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). Под редакцией В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М: ФГБУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России 2012Bulliard J.L., Panizzon R.G., Levi F. Epidemiology of epithelial skin cancers. Rev méd suisse 2009; 5: 884—888.Kim R.H., Armstrong A.W. Nonmelanoma skin cancer. Dermatologic Clinics 2012; 30: 125—139.Lemech C., Infante J., Arkenau H.T. The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol 2012; 4: 61—73.Balch C.M., Gershenwald J.E., Soong S.J. et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199—6206.Ko J.M., Velez N.F., Tsao H. Pathways to melanoma. Seminar in Cutaneous Medicine and Surgery 2010; 29: 210—217.Khaled M., Levy C., Fisher D.E. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes & Development 2010; 24: 2276—2281.Smalley K.S.M., Haass N.K., Brafford P.A. et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5: 1136—1144.Yazdi A.S., Ghoreschi K., Sander C.A. et al. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation. Eur J Dermatol 2010; 20: 575—579.Gelb B.D., Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Molec Genet 2006; 15: R220—R226.Гырылова С.Н., Рукша Т.Г., Комина А.В. и др. Анализ BRAF-статуса при меланоме кожи. Вестн дерматол венерол 2011; 6: 27—30.Smalley K.S.M., Nathanson K.L., Flaherty K.T. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009; 69: 3241— 3244.Hocker T.L., Songh M.K., Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J invest Derm 2008; 128: 2575—2595.Taube J.M., Begum S., Shi C. et al. Benign nodal nevi frequently harbor the activating V600E BRAF mutation. Am J Surg Pathol 2009; 33: 568—571.Davies M.A., Stemke-Hale K., Lin E. et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009; 15: 7538—7546.Curtin J.A., Fridland J., Kageshita T. Distinct sets of genetic alterations in melanoma. J invest Derm 2005; 126: 1660—1663.Wilhelm S.M., Adnane L., Newell P. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Therap 2008; 7: 3129— 3140.Jilaveanu L., Zito C., Lee S.J. et al. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin. Cancer Res 2009; 15: 1076—1085.Bollag G., Hirth P., Tsai J. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596—599.Flaherty K.T. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Int Medicine 2010; 153: 587—591.Aplin A.E., Kaplan F.M., Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J invest Derm 2011; 131: 1817—1820.Carvajal R.D., Antonescu C.R., Wolchok Jedd D. et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327—2334.Curtin J.A., Busam K., Pinkel D. et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340—4346.Rivera R.S., Nagatsuka H., Gunduz M. et a. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Archiv 2008; 452(1): 27—32.Antonescu C.R., Busam K.J., Francone T.D. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121: 257—264.Abysheva S.N., Iyevleva A.G., Efimova N.V. et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Research 2011; 21: 555—559.Chevallier P., Hunault-Berger M., Larosa F. et al. A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leukocyte Research 2009; 33: 1124—1126.Guo J., Si L., Kong Y. et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904—2909.Molhoek K.R., Brautigan D.L., Slingluff C.L. et al. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Translational Medicine 2005; 3: 39.Wang Y.F., Jiang C.C., Kiejda K.A. et al. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007; 13: 4934—4942.